SIG | Pregnancy Outcomes: Neurodevelopmental Outcomes in Children Born to Women and Men With Epilepsy

Tuesday, December 8, 2026 at 9:00 AM to 10:30 AM · 1 hr. 30 min. (America/Denver)
Special Interest Group

Information

In utero exposure to certain anti-seizure medications is associated with an increased risk of major congenital malformations in offspring, but also on child neurodevelopmental outcomes.

This session provides international evidence regarding child neurodevelopmental outcomes following in utero exposure to anti-seizure medications, and potential outcome modifiers (e.g., prenatal nutritional supplementation). Additionally, it reviews and discusses current knowledge regarding neurodevelopmental outcomes in the offspring of males with epilepsy taking anti-seizure medications.

It is important that health care professionals understand current research in order to optimize care and counseling for individuals with epilepsy of reproductive age.
Learning Objective 1
Describe neurodevelopmental outcomes of offspring exposed to anti-seizure medications in utero
Learning Objective 2
Understand the role of vitamin supplementation during pregnancy in affecting neurodevelopmental outcomes
Learning Objective 3
Explore whether there may be neurodevelopmental impacts on the offspring of men with epilepsy
Target Audience
CliniciansFellows/TraineesAdvanced Practice Providers (APPs)AdvocatesBehavioral Health ProvidersCommunity Health WorkersNursesPharmacistsScientists/ResearchersSocial WorkersTechnicians
Career Stage
Early Career (typically 0-5 years from completion of training)Mid-Career (typically 6-15 years from completion of trainingSenior (typically >15 years from completion of training)
Demographics
ClinicalYoung ProfessionalsResearchFirst-time Attendee
Session Content Includes
Patient PerspectivePediatric
Education Credits
1.5 CME1.5 CNE1.5 CPE
Session ID
PREGNANCYSIG26
Presentation Id
3452251
Event ID
24056
Session Type
Session